Literature DB >> 300758

Sequential proliferation induced in human peripheral blood lymphocytes by mitogen. I. Growth of 1000 lymphocytes in feeder layer cultures.

L A Winger, P C Nowell, R P Daniele.   

Abstract

A culture system is described in which 1000 human peripheral blood lymphocytes diluted in 2.5 x 10(5) mitomycin-treated autologous cells respond to phytohemagglutinin (PHA). Proliferation data, including 3HTdR uptake, cell survival counts, and mitotic indices, indicate that this inoculum expands from 1000 to 40,000 cells by day 7, suggesting five or six sequential cell divisions. Chromosome markers in allogeneic cultures demonstrate that the dividing cells are derived from the original 1000 cells and not from the "feeder layer" of mitomycin-treated lymphocytes. The time course of proliferation in this system is similar to that in other human lymphocyte culture systems with a low percentage of responding cells, as in the response to PHA of cells from patients with chronic lymphocytic leukemia or the response of normal lymphocytes to antigens. The conditions provided by the feeder layer which permit proliferation of this small number of lymphocytes are not precisely known, but erythrocytes, heat-killed lymphocytes, or inert particles do not provide a satisfactory substitute.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 300758

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Help and suppression by lymphoid cells as a function of cellular concentration.

Authors:  J Farrant; S C Knight
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

2.  Activation of human T-lymphocytes. A kinetic and stereological study.

Authors:  G E Petrzilka; H E Schroeder
Journal:  Cell Tissue Res       Date:  1979-09-02       Impact factor: 5.249

3.  Kinetics of mitogen-induced proliferation and differentiation of human peripheral blood B lymphocytes.

Authors:  T V Shankey; R P Daniele; P C Nowell
Journal:  Clin Exp Immunol       Date:  1981-04       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.